Eric Joseph
Stock Analyst at JP Morgan
(2.06)
# 3,041
Out of 5,148 analysts
124
Total ratings
39.29%
Success rate
-5.03%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Upgrades: Overweight | $10 → $11 | $3.50 | +214.29% | 3 | Dec 17, 2025 | |
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $28.60 | +71.33% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $27.37 | +68.07% | 4 | Oct 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $87.34 | -26.72% | 4 | Jun 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $44 → $7 | $4.75 | +47.52% | 4 | May 28, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $4.26 | - | 5 | May 20, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $9.55 | -26.70% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $64.20 | +4.36% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.19 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.24 | - | 4 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $30 | $15.22 | +97.17% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $8.78 | +59.45% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $100.13 | -29.09% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $27.62 | +37.58% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $4.32 | +433.02% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $13.47 | +26.21% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $9.83 | +113.63% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $14.74 | -32.16% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.29 | +1,062.79% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.85 | +110.53% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $17.49 | -37.11% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $23.10 | +332.90% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $2.20 | +127.79% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.71 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $40.41 | -72.78% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $26.35 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $9.27 | +1,194.50% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $6.79 | +4,321.52% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $11.42 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.60 | +462.50% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.24 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.32 | +1,710.34% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $3.56 | +265.68% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.40 | +2,650.00% | 3 | Nov 14, 2018 |
Recursion Pharmaceuticals
Dec 17, 2025
Upgrades: Overweight
Price Target: $10 → $11
Current: $3.50
Upside: +214.29%
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $28.60
Upside: +71.33%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $27.37
Upside: +68.07%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $87.34
Upside: -26.72%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Neutral
Price Target: $44 → $7
Current: $4.75
Upside: +47.52%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.26
Upside: -
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $9.55
Upside: -26.70%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $64.20
Upside: +4.36%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.19
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.24
Upside: -
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $15.22
Upside: +97.17%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $8.78
Upside: +59.45%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $100.13
Upside: -29.09%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $27.62
Upside: +37.58%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $4.32
Upside: +433.02%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $13.47
Upside: +26.21%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $9.83
Upside: +113.63%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $14.74
Upside: -32.16%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.29
Upside: +1,062.79%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.85
Upside: +110.53%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $17.49
Upside: -37.11%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $23.10
Upside: +332.90%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $2.20
Upside: +127.79%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $4.71
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $40.41
Upside: -72.78%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $26.35
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $9.27
Upside: +1,194.50%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $6.79
Upside: +4,321.52%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $11.42
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.60
Upside: +462.50%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.24
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.32
Upside: +1,710.34%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $3.56
Upside: +265.68%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.40
Upside: +2,650.00%